Objective: To investigate the therapeutic role of trovafloxacin mesylate, a newer-generation fluoroquinolone with an expanded spectrum of activity, in the treatment of experimental bacterial keratitis.
M

ICROBIAL KERATITIS
continues to be a common, potentially sightthreatening ocular infection.
1,2 Fluoroquinolones are increasingly selected as initial, broad-spectrum agents for the topical therapy of bacterial keratitis. 3 The use of ofloxacin and ciprofloxacin, as single agents, was shown in clinical trials to be comparable to a combination of fortified antibiotics in the treatment of acute bacterial keratitis. 4, 5 However, these 2 quinolones, which currently are often used, have limited in vitro activity against some grampositive organisms and various strains of Pseudomonas aeruginosa. 6, 7 Trovafloxacin mesylate, 7-(3-azabicyclo [3, 1, 0] hexyl)-naphthyridone, is a newer-generation synthetic fluoroquinolone currently available for oral and intravenous administration. Trovafloxacin has broad spectrum antibacterial activity against gram-negative, gram-positive, and anaerobic bacteria. In vitro and in vivo studies [8] [9] [10] [11] [12] [13] in systemic diseases have demonstrated a greater activity against clinically important gram-positive organisms (most notably streptococci), while maintaining activity against gram-negative organisms, when compared with ciprofloxacin and ofloxacin.
The purpose of this study is to determine the microbiological efficacy of topical trovafloxacin for potential use in therapy of experimental bacterial keratitis. After performing susceptibility and pharmacokinetic studies, we studied the microbiological effect of topical trovafloxacin on bacterial keratitis caused by either gram-positive organisms, such as Staphylococcus aureus and Streptococcus pneumoniae, or a gram-negative organism (P aeruginosa) and compared its efficacy with that of ciprofloxacin and ofloxacin.
LABORATORY SCIENCES
METHODS
BACTERIAL STRAINS
Bacterial strains used in this study were clinical ocular isolates collected from corneal specimens at the Wilmer Ophthalmological Institute, Baltimore, Md.
ANTIMICROBIAL SUSCEPTIBILITY STUDIES
Minimum inhibitory concentrations (MICs) of trovafloxacin, ciprofloxacin, and ofloxacin were determined for various ocular isolates of S aureus, S pneumoniae, Staphylococcus epidermidis, P aeruginosa, and Haemophilus influenzae. The E-test method was used for determining the MIC for each strain. The bacterial suspension was prepared by collecting the clinical isolates from a blood agar plate. The isolate sample was adjusted with 0.9% nonbacteriostatic isotonic sodium chloride solution to achieve the same density as a 0.5 McFarland standard (1 ϫ 10 8 colony-forming units/mL). The appropriate E-test strip was placed on a Mueller-Hinton II agar plate (BBL, Cockeysville, Md) inoculated with the suspension of bacteria. The plates were incubated for 16 to 24 hours at 37°C, and the MIC was read from the scale on the side of the strip at the point where the ellipse of growth inhibition intercepted the strip. All the tests were performed in duplicate.
PHARMACOKINETIC STUDIES
The pharmacokinetic studies were performed on rabbit eyes. Twelve rabbits were used for this study. Epithelial removal (to promote antibiotic entry and to simulate human ulcerative keratitis) was evaluated. In each rabbit, one eye underwent removal of the central (7.5 mm) corneal epithelium, and in the fellow eye the epithelium remained intact. A single drop of trovafloxacin was applied to both eyes. Rabbits were humanely killed at 15, 30, 60, 120, and 240 minutes (at each time point, 3 rabbits were euthanized), and samples were obtained immediately thereafter from aqueous humor, vitreous, and the central cornea (7.5 mm). The tissue concentration of trovafloxacin was determined using a high-performance liquid chromatography assay.
14
BACTERIAL KERATITIS STUDIES
In these studies, 72 (24 in each experiment) New Zealand white rabbits, weighing 2.0 to 2.25 kg, were used in accordance with the guidelines for animal experimentation established by the Association of Research in Vision and Ophthalmology (Rockville, Md); approval from the appropriate institutional review board was obtained for the study, and the institutional guidelines regarding animal experimentation were followed. All rabbits were sedated and anesthetized with intramuscular injection of ketamine hydrochloride (60 mg/kg) and xylazine hydrochloride (12 mg/kg) and topical 0.5% proparacaine hydrochloride before having only one eye of each animal injected with bacteria.
To produce keratitis, 10 3 colony-forming units (0.1 mL) of clinical bacterial isolates in logarithmic growth phase were injected into the corneal stroma in one eye. The injection was performed with a 30-gauge needle into the stroma in the central part of the cornea under microscopic guidance. The first experiment was performed with 24 rabbits, using a clinical isolate of a methicillin-sensitive S aureus with a predetermined MIC50 (inhibits 50% of strains) of 0.5 µg/mL for ciprofloxacin. The other 2 experiments were performed in an identical fashion by inoculating either S pneumoniae or P aeruginosa.
Twelve hours after the injection, the rabbits were randomized to 4 treatment groups, with 6 rabbits in each group: (1) ciprofloxacin, 3 mg/mL (Ciloxan 0.3%; Alcon Laboratories, Fort Worth, Tex); (2) ofloxacin, 3 mg/mL (Ocuflox 0.3%; Allergan, Irvine, Calif); (3) trovafloxacin mesylate, 5 mg/mL (Trovan-IV; Pfizer, New York, NY); and (4) preservative-free 0.9% nonbacteriostatic isotonic sodium chloride solution for intravenous use (control). Trovafloxacin eyedrops were prepared using the intravenous solution that was transferred into a dropper bottle under a sterile hood.
The eyedrops were administered every hour for 12 hours. One hour after the last dose of eyedrops, the rabbits were systemically anesthetized and then humanely killed by intracardiac injection of pentobarbital sodium (Beuthanasia-D Special; Schering-Plough Animal Health Corp, Kenilworth, NJ). The rabbits' corneas were excised using a sterile, disposable, 7.5-mm corneal trephine and irrigated with 3 mL of phosphatebuffered saline to eliminate any residual antibiotic or debris on the surface of the corneas. The corneal buttons were immediately homogenized and then serially diluted before plating in duplicate on blood agar for S aureus and S pneumoniae and on Mueller-Hinton II agar for P aeruginosa. The specimens were incubated at 35°C for 24 hours before quantitative bacteriologic analysis.
RESULTS
ANTIMICROBIAL SUSCEPTIBILITY STUDIES
The MICs for the various ocular strains are given in Table 1 . The MIC for P aeruginosa strains was significantly lower for ciprofloxacin compared with trovafloxacin (P = .008) and ofloxacin (P = .007) and significantly lower for trovafloxacin compared with ofloxacin (P=.007).
The MIC for S aureus strains was significantly lower for trovafloxacin compared with ciprofloxacin (PϽ.001) and ofloxacin (PϽ.001), and no significant difference was found between the MIC for ciprofloxacin and ofloxacin (P=.10). The MIC for H influenzae strains was significantly lower for trovafloxacin (P =.005) and ciprofloxacin (P=.005) compared with ofloxacin. No significant difference was found between trovafloxacin and ciprofloxacin (P =.44). The MIC for S epidermidis was lower for trovafloxacin than ciprofloxacin; however, this was not statistically conclusive (P=.07). The MIC for S pneumonia strains was significantly lower for trovafloxacin (P=.006) and ciprofloxacin (P=.006) compared with ofloxacin.
PHARMACOKINETIC STUDIES
After the single trovafloxacin drop application, a substantial penetration was found in the corneas at all time points ( Table 2) . Mean (SD) trovafloxacin levels were higher in eyes with denuded epithelium (25. 
BACTERIAL KERATITIS STUDIES
The bacterial counts for the 3 studies are given in Table 3 . The S aureus keratitis study showed a statistically significant decrease in bacterial counts in the groups treated with trovafloxacin compared with the ciprofloxacin and ofloxacin treatment groups (P = .002). The S pneumoniae study showed a significant decrease in bacterial counts in the antibiotic-treated groups compared with the controls (P = .002) and a significant decrease in bacterial counts in the trovafloxacin groups compared with ciprofloxacin but not ofloxacin. The P aeruginosa study showed a significant decrease in all antibiotic-treated groups compared with the control group (PϽ.001).
COMMENT
Until recently, the fluoroquinolones were primarily agents with excellent activity against gram-negative bacilli but with questionable activity against some important grampositive pathogens. Newer agents under development have an expanded profile of antibacterial activity against grampositive pathogens, including staphylococci, streptococci, enterococci, and anaerobic isolates. The fluoroquinolone evolutionary tree has 2 main branches. The first branch is the naphthyridine series, which have a nitrogen atom at the C-8 position (eg, nalidixic acid, enoxacin, tosufloxacin, trovafloxacin); all others are fluoroquinolone agents, with the C-7 position being the most adaptable site for chemical substitution.
A major clinical challenge has been the worldwide emergence and spread of antimicrobial resistance, especially among gram-positive isolates, such as pneumococci. There is recent information on the mechanism of action of fluoroquinolone and how resistance develops. From this, it seems that the most efficient use of these fluoroquinolone compounds is to use a highly active agent with a favorable pharmacodynamic profile for the shortest treatment duration consistent with cure.
Trovafloxacin is a newer-generation, expandedspectrum fluoroquinolone, which was shown in our study to have in vitro potency, favorable pharmacokinetics, and in vivo efficacy, suggesting a potential role in the therapy of bacterial keratitis. The use of topical fluorinated quinolones has become a frequent, initial, single-agent therapy for bacterial keratitis. 4, 5 The mechanism of action of the quinolones is via inhibition of the type II topoisomerase DNA gyrase, an essential bacterial enzyme that alters the topology of double-stranded DNA within the cell. Inhibition of this activity by fluoroquinolones is associated with rapid killing of the bacterial cell. 15 The important advantages in the systemic use of trovafloxacin are the pharmacokinetic properties and its expanded antibacterial spectrum, especially against grampositive organisms, including Streptococcus species. Our results showed that trovafloxacin not only is effective against P aeruginosa, similar to other experimental keratitis studies, 16, 17 but also is superior as far as activity against gram-positive bacteria. [18] [19] [20] [21] [22] The current clinical use of trovafloxacin so far has been systemic, intravenous, intramuscular, or oral. The intravenous formulation of trovafloxacin is the prodrug alatrofloxacin mesylate, which has little intrinsic anti- bacterial activity in vitro but demonstrates good activity in vivo as a result of undergoing rapid hydrolysis and is rapidly converted to trovafloxacin after intravenous administration. We used the intravenous formulation for preparation of the eyedrops, and this demonstrated a good antibacterial activity in topical use for the keratitis model. In vitro activity of trovafloxacin has been shown to be superior to both ciprofloxacin and ofloxacin against both the penicillin-susceptible and penicillin-resistant pneumococci. 23, 24 In our study the in vitro antibacterial activity of trovafloxacin against ocular isolates has been demonstrated by using the E-test, a modification of a disc diffusion susceptibility testing. 25 Pascual et al 26 showed that trovafloxacin penetrates into phagocytic and nonphagocytic cells, reaching intracellular concentrations several times greater than the extracellular ones, whereas it remained active intracellularly in human polymorphonuclear leukocytes; this fact may enhance the in vivo antibacterial activity. Lately, the systemic use of trovafloxacin was restricted to lifeor limb-threatening conditions due to several reports of hepatic toxicity after systemic use of the drug. 27, 28 With topical ocular use, the expected systemic levels are extremely low, if detectable at all; moreover, the restricted systemic use may offer an advantage with the topical use due to a lesser chance of emergence of resistance. In conclusion, the high in vitro efficacy against ocular isolates along with the high ocular tissue penetration and nondetectable systemic levels and in vivo efficacy indicate that trovafloxacin may have an important clinical role in the topical treatment of bacterial keratitis, including streptococcal species.
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